Vaccination with recombinant modified vaccinia virus Ankara expressing bovine respiratory syncytial virus (bRSV) proteins protects calves against RSV challenge (Q45404021)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Vaccination with recombinant modified vaccinia virus Ankara expressing bovine respiratory syncytial virus (bRSV) proteins protects calves against RSV challenge	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Vaccination with recombinant modified vaccinia virus Ankara expressing bovine respiratory syncytial virus (bRSV) proteins protects calves against RSV challenge (English)

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

object named as

vaccinia virus

1 reference

based on heuristic

inferred from title

6

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

3

object named as

Yasemin Suezer

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

author name string

Adriaan F G Antonis

1

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Robbert G van der Most

2

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Norbert Stockhofe-Zurwieden

4

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Franz Daus

5

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Remco S Schrijver

7

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

language of work or name

0 references

publication date

20 April 2007

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

25

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

25

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

4818-4827

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Vaccine-Induced Immunopathology during Bovine Respiratory Syncytial Virus Infection: Exploring the Parameters of Pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.002

7 January 2021

Respiratory syncytial virus: reverse genetics and vaccine strategies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.002

7 January 2021

Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.002

7 January 2021

MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author's transl)

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.002

7 January 2021

Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.002

7 January 2021

Protective immunity in macaques vaccinated with a modified vaccinia virus Ankara-based measles virus vaccine in the presence of passively acquired antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.002

7 January 2021

Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.002

7 January 2021

MVA: a cuckoo in the vaccine nest?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.002

7 January 2021

Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.002

7 January 2021

A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.002

7 January 2021

Clinical protocol. A phase II study: efficacy of the gene therapy of the MVA E2 recombinant virus in the treatment of precancerous lesions (NIC I and NIC II) associated with infection of oncogenic human papillomavirus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.002

7 January 2021

Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.002

7 January 2021

Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.002

7 January 2021

Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.002

7 January 2021

Priming and boosting immunity to respiratory syncytial virus by recombinant replication-defective vaccinia virus MVA.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.002

7 January 2021

Vaccination of infant macaques with a recombinant modified vaccinia virus Ankara expressing the respiratory syncytial virus F and G genes does not predispose for immunopathology

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.002

7 January 2021

Transient host range selection for genetic engineering of modified vaccinia virus Ankara

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.002

7 January 2021

Improved host range selection for recombinant modified vaccinia virus Ankara

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.002

7 January 2021

Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.002

7 January 2021

Experimental reproduction of respiratory disease in calves with non-cell-culture-passaged bovine respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.002

7 January 2021

Type-specific serologic diagnosis of respiratory syncytial virus infection, based on a synthetic peptide of the attachment protein G.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.002

7 January 2021

Rapid quantification of SIV-specific CD8 T cell responses with recombinant vaccinia virus ELISPOT or cytokine flow cytometry.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.002

7 January 2021

Kinetics of antiviral CD8 T cell responses during primary and post-vaccination secondary bovine respiratory syncytial virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.002

7 January 2021

The acute phase response of haptoglobin and serum amyloid A (SAA) in cattle undergoing experimental infection with bovine respiratory syncytial virus.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.002

7 January 2021

Replication and clearance of respiratory syncytial virus: apoptosis is an important pathway of virus clearance after experimental infection with bovine respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.002

7 January 2021

Monoclonal antibodies against bovine immunoglobulins and their use in isotype-specific ELISAs for rotavirus antibody

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.002

7 January 2021

Immunopathogenesis of vaccine-enhanced RSV disease.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.002

7 January 2021

RSV-induced immunopathology: dynamic interplay between the virus and host immune response

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.002

7 January 2021

Recombinant vaccinia virus-induced T-cell immunity: quantitation of the response to the virus vector and the foreign epitope

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.002

7 January 2021

Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.002

7 January 2021

Recombinant vaccinia viruses expressing the F, G or N, but not the M2, protein of bovine respiratory syncytial virus (BRSV) induce resistance to BRSV challenge in the calf and protect against the development of pneumonic lesions

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.002

7 January 2021

Evaluation of BBG2Na in infant macaques: specific immune responses after vaccination and RSV challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.002

7 January 2021

Protective and disease-enhancing immune responses induced by recombinant modified vaccinia Ankara (MVA) expressing respiratory syncytial virus proteins.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.002

7 January 2021

Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.002

7 January 2021

Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.002

7 January 2021

An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.002

7 January 2021

Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.002

7 January 2021

Recombinant poxviruses as mucosal vaccine vectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.002

7 January 2021

A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.002

7 January 2021

Identifiers

10.1016/J.VACCINE.2007.04.002

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45404021&oldid=2076639513"